The Dual PI3K/mToR Inhibitor Omipalisib/GSK2126458 Inhibits Clonogenic Growth in Oncogenically-transformed Cells from Neurocutaneous Melanocytosis.,Cancer Genomics & Proteomics

当前位置： X-MOL 学术 › Cancer Genom. Proteom. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The Dual PI3K/mToR Inhibitor Omipalisib/GSK2126458 Inhibits Clonogenic Growth in Oncogenically-transformed Cells from Neurocutaneous Melanocytosis.
Cancer Genomics & Proteomics ( IF 2.5 ) Pub Date : 2018-7-7 , DOI: 10.21873/cgp.20082
Dipanjan Basu ₁ , Cláudia M Salgado ₂ , Bruce Bauer ₃ , Yasmin Khakoo _{4,

5} , Janki R Patel ₆ , Ryan M Hoehl ₆ , Dominique M Bertolini ₆ , Joie Zabec ₆ , Morgan R Brzozowski ₆ , Miguel Reyes-Múgica ₂

Affiliation

Omipalisib has been found to affect the viability of cancer cells. However, its effect on clonogenicity - a feature of cancer stem cells, is not clear. Cells isolated from neurocutaneous melanocytosis (NCM) patients' lesions grow clonogenically. The aim of this study was to investigate the effect of omipalisib treatment on clonogenic growth of NCM cells in vitro.

中文翻译：

双重PI3K / mToR抑制剂Omipalisib / GSK2126458抑制神经皮肤黑素瘤致癌转化细胞中的克隆生长。

已发现Omipalisib影响癌细胞的生存能力。但是，其对克隆形成性（癌症干细胞的特征）的影响尚不清楚。从神经皮肤黑素细胞增多症（NCM）患者的病变中分离出的细胞会克隆生长。这项研究的目的是研究奥米沙利治疗对体外NCM细胞克隆生长的影响。

更新日期：2020-08-21

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>